Nilsine Partners LLC Takes $3.07 Million Position in argenex SE $ARGX

Nilsine Partners LLC purchased a new position in argenex SE (NASDAQ:ARGX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,653 shares of the company’s stock, valued at approximately $3,072,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ARGX. Abound Wealth Management raised its stake in argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after buying an additional 32 shares in the last quarter. Ameriflex Group Inc. purchased a new stake in argenex during the third quarter worth $32,000. Aventura Private Wealth LLC bought a new stake in argenex during the 4th quarter valued at $38,000. Sunbelt Securities Inc. purchased a new position in shares of argenex in the 3rd quarter valued at $36,000. Finally, Bessemer Group Inc. increased its holdings in shares of argenex by 276.5% in the 3rd quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after acquiring an additional 47 shares during the period. 60.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on ARGX. DZ Bank raised argenex to a “strong-buy” rating in a research report on Friday, December 19th. Royal Bank Of Canada cut their target price on argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research note on Friday, February 27th. Morgan Stanley boosted their target price on shares of argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, HC Wainwright raised their price target on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $999.22.

argenex Trading Up 3.7%

Shares of ARGX opened at $730.25 on Wednesday. The firm has a market cap of $45.19 billion, a PE ratio of 37.41, a P/E/G ratio of 1.16 and a beta of 0.38. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The stock has a fifty day moving average price of $777.55 and a 200-day moving average price of $813.68.

argenex (NASDAQ:ARGX) last announced its earnings results on Saturday, February 14th. The company reported $8.02 earnings per share for the quarter. argenex had a return on equity of 38.51% and a net margin of 30.42%. As a group, research analysts forecast that argenex SE will post 3.13 EPS for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.